SSY GROUP(02005): Obtained drug manufacturing registration for 5ml:100mg injection of dexmedetomidine hydrochloride.

12:04 03/03/2026

Shi Si Medicine Group (02005) announced that the group has obtained the drug production registration certificate for the injection of desmopressin hydrochloride (5ml:100mg) from the Chinese State Food and Drug Administration. It belongs to the third class of chemical drugs and is considered equivalent through consistency evaluation. The desmopressin hydrochloride injection of the group is the first domestic enterprise to be approved and is mainly used in the treatment of respiratory failure.

SSY GROUP (02005) announced that the group has obtained the drug production registration certificate for the hydrochloride of dexamethasone injection (5ml:100mg) from the China National Medical Products Administration. It belongs to the category 3 of chemical drugs and is considered to have passed the consistency evaluation. The hydrochloride of dexamethasone injection by the group is the first approved by a domestic enterprise and is mainly used for the treatment of respiratory failure.

TIANGONG INT'L (00826) subsidiary intends to invest 3 million yuan to further subscribe for 293,900 shares of new shares in Shanghai Geze, increasing its shareholding to approximately 10.53%.

MNSO (09896) spent $222,500 to repurchase 51,300 shares on March 2nd.

Oppenheimer March US stock strategy: Momentum strategy is timely, recommending stocks such as Apple Inc. (AAPL.US), Alcoa Corporation (AA.US), Baker Hughes (BKR.US), etc.

TIANGONG INT'L (00826) subsidiary intends to invest 3 million yuan to further subscribe for 293,900 shares of new shares in Shanghai Geze, increasing its shareholding to approximately 10.53%.

MNSO (09896) spent $222,500 to repurchase 51,300 shares on March 2nd.

Oppenheimer March US stock strategy: Momentum strategy is timely, recommending stocks such as Apple Inc. (AAPL.US), Alcoa Corporation (AA.US), Baker Hughes (BKR.US), etc.